tbuckley/cabot-search huggingface dataset:
Abstract 006: Neighbourhood Deprivation And Morbid Obesity: Insights From Houston Methodist Outpatient Learning Health System Registry
Authors: nwabunie nwana, Mohamad Taha, RAKESH GULLAPELLI, Charlie Nicolas, Stephen Jones, Safi U Khan, Zulqarnain Javed, Priyanka Satish, Shivani Mahajan, Miguel Cainzos Achirica, Khurram Nasir
Journal: Circulation (2022)

Introduction: Area Deprivation Index (ADI), a proxy measure for neighbourhood socioeconomic context, is informative for prioritizing limited resources in improving health outcomes. With emerging therapeutic options to improve cardiometabolic health among individuals with morbid obesity, whether available measures, such as ADI, for integrated health systems can identify this subpopulation at risk is unknown. Methods: This cross-sectional study analyzed data from 865,995 adult patients in the Houston Methodist Outpatient Learning Health System Registry between June 1 st , 2016 and July 20 th , 2021. Using University of Wisconsin-Madison School of Medicine’s ADI dataset, each patient was assigned an ADI rank according to the census block group of their geocoded residential address. BMI was calculated based on recorded height and weight. Patients with non-geocoded addresses (n=9 855), missing and abnormal BMI values (n=107 037) were excluded. Multinomial logistic regression models were used to examine the association between ADI and morbid obesity (BMI≥40 kg/m 2 ). Results: A total of 751,174 adults with an ADI ranking were included in the analysis. Overall, the prevalence of morbid obesity was 6.9% (n=51,609). The age-adjusted prevalence of morbid obesity increased across worsening neighborhood deprivation in overall population and across racial/ethnic subgroups (Figure 1). Each ADI rank increase in neighborhood disadvantage was associated with an unadjusted odds ratio (OR) of 1.022 (95% CI, 1.022-1.023) for morbid obesity compared to normal weight. After adjusting for age, sex and race/ethnicity, we found a statistically significant association of worst vs least level of neighborhood deprivation with patients with morbid obesity compared to normal weight (aOR, 3.75; 95% CI, 3.60-3.89). Conclusion: The study highlights utility of census-based measures to identify patients living in socioeconomically deprived areas for comprehensive morbid obesity management strategies.
Abstract 10340: Higher Prevalance of Non-Group 1 Pulmonary Hypertension in Admissions Among Cancer Survivors with Worse In-Hospital Outcomes- A Nationwide Analysis
Authors: Bisharah Rizvi, Srija Shanker, Mimoza Isufi, Ashish Nepal, Deepu Joseph, Tanvi Singla, Aamer Mohammad, Zainab Gandhi, Rupak Desai
Journal: Circulation (2021)

Introduction: Pulmonary hypertension (PH) in cancer patients is an underrecognized problem. It can be secondary to malignancy, medications, thromboemboli in lung, and underlying cardiac or lung disease. Outcomes of PH in cancer survivors have not been studied before. The objective of this study is to study the prevalence and impact of Non-group 1 PH on admissions among cancer survivors. Methods: The National Inpatient Sample (October, 2015 to 2017), was used to identify all adult hospitalizations among cancer survivors with PH using ICD-10 codes. Primary outcome were prevalence and demographics of PH in cancer survivors. Secondary outcomes were in-hospital mortality and healthcare resource utilization. Results: Of 6,003,538 weighted nationwide admissions of cancer survivors, 4.7% (282,810) had non-group 1 PH. The prevalence of PH was higher in patients with prior cancers compared to other admissions (4.7% vs. 3.3%, p&lt;0.001). It was higher in females than males (5.1% vs. 4.3%). Most common in blacks (5.9%), followed by whites (4.7%), Native American (4.1%), Asian or Pacific Islander (3.8%), others (3.7%) and Hispanics (3.3%) (Fig. 1) . Hypertension, Diabetes, smoking, obesity, renal failure, congestive heart failure, valvular heart disease and chronic pulmonary disease were higher in PH group. In-hospital outcomes in cancer survivors with vs. without PH showed significantly higher all-cause inpatient mortality in PH group (OR1.34, 95% CI=1.31-1.37, p&lt;0.001) with fewer routine discharges (39.3% vs. 52.1%, p&lt;0.001), higher transfer rate to short-term hospital, and other facilities (skilled nursing care/intermediate care facility), higher home health care requirement, prolonged hospital stay (4 vs 3 days), and higher cost ($10,325 vs. $9163) per admission. Conclusion: This is the first large-scale study to demonstrate the higher burden and worse in-hospital outcomes of non-group 1 PH in cancer survivors. Early diagnosis and treatment is necessary.
Abstract P094: Awareness Of Cardiovascular Disease Is Low Among Young Women And Varies By Region
Authors: Sierra Patterson, Hannah Palfrey, Sarah D De Ferranti, Holly Gooding
Journal: Circulation (2022)

Background: Prior research has shown that awareness of cardiovascular disease (CVD) and its risk factors is low among young women. The present study used preliminary data to compare the awareness of CVD in young women seen in primary care clinics in the Northeastern and Southeastern United States. Methods: We recruited 370 females ages 15-24 years from two primary care clinics located in Boston, MA (n=331) and Atlanta, GA (n=39). Recruitment in Atlanta, GA is ongoing. Participants completed a modified version of the AHA Women’s Health Survey. We examined the relationship between location and 1) knowledge about CVD and 2) engagement in preventive behaviors, while controlling for race/ethnicity, age group, and primary caregiver education. Results: Sixty-two percent (n=23) of young women in Atlanta reported feeling informed about CVD, while 53% (n=163) of young women in Boston reported feeling informed about CVD. Only 13% (n=34) of participants in Boston and 6% (n=2) of participants in Atlanta correctly identified CVD as the leading cause of death for women. Participants in Atlanta were less likely to report engagement in CVD preventive behaviors such as exercising (OR: 0.32, 95% CI: 0.12, 0.91), maintaining a healthy cholesterol (OR: 0.13, 95% CI: 0.04, 0.50) or blood pressure level (OR: 0.24, 95% CI: 0.08, 0.74), and reducing sugar in their diet (OR: 0.33, 95% CI: 0.12, 0.91). Moreover, young women in Atlanta were more than twice as likely to report having never discussed CVD-related health topics such as family history of CVD, blood pressure, and cholesterol with their health care provider (OR: 2.46, 95% CI: 0.86, 7.02). Conclusion: CVD awareness is low among young women and varies by region. Despite living in a region where CVD is highly prevalent, young women in Atlanta were less likely to engage in preventive behaviors and less likely to discuss CVD-related topics with their health care provider. In this region where cardiovascular health disparities are common, opportunities remain to promote heart healthy behavior among young women to reduce CVD risk.
Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial
Authors: Rajeka Lazarus, Sarah Baos, Heike Cappel-Porter, Andrew Carson-Stevens, Madeleine Clout, Lucy Culliford, Stevan R Emmett, Jonathan Garstang, Lukuman Gbadamoshi, Bassam Hallis, Rosie A Harris, David Hutton, Nick Jacobsen, Katherine Joyce, Rachel Kaminski, Vincenzo Libri, Alex Middleditch, Liz McCullagh, Ed Moran, Adrian Phillipson, Elizabeth Price, John Ryan, Russell Thirard, Rachel Todd, Matthew D Snape, David Tucker, Rachel Lauren Williams, Jonathan S Nguyen-Van-Tam, Adam Finn, Chris A Rogers, Kirsty Adams, Seema Alaee, Parvinder K. Aley, Emma Allum, Sally Anthony, Kate Ashton, Tanya Awal, Liz Barnett, Alison Barratt, Charlotte Barron, Holly Baum, Chloe Beard, Lorna Bennett, Samuel Bird, Sarah Bishop, Jess Bisset, Pritesh Bodalia, Jane Bowles, Catherine Bowyer, Kirstie Bradburn, Jonathan J.H. Bray, Catherine Bressington, Matthew Brimfield, Lauren Broad, Pauline Brown, Ruth Brydon-Hill, Sharon Burge, David Carmichael, Gurjit Chohan, Tonia Clark, Adrianne Close, Tom Coleman, Claire Cowley, Charlotte Cranfield, Eleanor Cross, Alyssa D'Agostino, Silvia D'Arcangelo, Ashley David Otter, Kate Davies, Catrin Davies, Ru Davies, Louisa Davies, Kimberley Driver, Charlotte Eglinton, Charlotte Ekblad, Emma Eldridge, Teriann Evans, Mim Evans, Isabel Evans, Yama F Mujadidi, Amanda Farrow, Beverley Faulkner, Sally Feltham, Susan Figueirido, Jamie Ford, David Foxwell, Sharon Frayling, Sophie Gardiner, Karen E. Gooch, Jayne Goodwin, Alice Halliday, Shama Hamal, Sarah Harrhy, Andrew Harris, Lesley Haxton, Matthew Haynes, Mae Hazell, Tracey Hembrough, Jacqueline Hewson, Bethany Hicks, Thomas Higgins, Michelle Hill, Alex Hills, Zoe Hilton, Benjamin Hitchings, Cheryl Hua, Hina Iftikhar, Attya Iqbal, Laura Jones, Nicola Jones, Johanna Kellett Wright, Sarah Kidd, Alison Kirby, Lucy Knibbs, Jenny Lamb, Helen Langton, Rwth Leach, Phoebe Lewis-Clarke, Amy Lloyd, Kirsty Maclean, Nicola Manning, Anthony Marriott, Isobel Joy McFadzean, Maeve McLaughlin, Alison McQueen, Bianca Mills, Gurudutt Naik, Lisa Nicholls, Chris Norman, Keren Northcott, Kerry Nyland, Catherine Oliver, Elizabeth Oliver, Jennifer Oliver, Diana Owen, Jemma Paterson, Lauren Pearce, Suzannah Pegler, Zoe Price, William B. Pynsent, Lidia Ramos, Tommy Rampling, David Rea, Karen Regan, Tawassal Riaz, Marivic Ricamara, Danielle Rice, Melody Rich, Marianne Roots, Kathryn Ann Ryan, Yukari Sakagami, Ahmed Salem, Jade Salter-Hewitt, Michelle Samuels, Silvia Santoloce, Siwan Seaman, Michael Seneviratne, Sara Shankland, Louise Silva, Katie Smart, Rachel M. Smith, Joyce Smith, Rebecca Stringer, Helen Talbot, Teresa Tarling, Sarah Louise Taylor, Amy Thomas, Grace Tilzey, Gina Townley, Lisa Trembath, Kate Turkentine, Kelly Turner, Jenny Tyler, Jacinta Ugoji, Katharine Wale, Terrie Walker-Smith, Maggie Walton, Barbara Warnes, Sarah Whittley, Jennie Williams, Gail Williams, Kevin Williamson, Yee Ting Nicole Yim, Nicola Youlden
Journal: The Lancet (2021)
Abstract P020: High Sensitivity C-reactive Protein Is Associated With Incidence Of Metabolic Syndrome Among Hispanic/Latino Participants Of The Hispanic Community Health Study/Study Of Latinos
Authors: Robert A Mesa, Neil Schneiderman, Maria Llabre, Ana Palacio, Tali Elfassy
Journal: Circulation (2022)

Introduction: High Sensitivity C-reactive protein (HsCRP) is a non-specific marker of systemic inflammation. Elevated levels of HsCRP have been shown to be predictive of cardiovascular disease and cardiovascular related events. The relationship between HsCRP and longitudinal onset of metabolic syndrome (MetS) has not been fully elucidated, especially among U.S. Hispanics/Latinos, which is a growing diverse group in the U.S. Objectives: To determine whether HsCRP is associated with incident MetS among U.S. Hispanics/Latinos. Methods: The Hispanic Community Health Study/Study of Latinos is a longitudinal observational cohort assessing cardiovascular health among diverse U.S. Hispanics/Latinos. HsCRP was measured at visit 1 (2008-2011) using a Roche Modular Chemistry Analyzer. HsCRP was classified as low, moderate, or high, based on ACC/AHA guidelines. All MetS components (abdominal obesity, triglycerides, HDL cholesterol, blood pressure, and fasting glucose) were measured at visit 1 and visit 2 (2014-2017). MetS was defined as the presence of three or more components based on the definition from the Third Report of the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III). Participants free of MetS at visit 1 and with complete data on HsCRP and all MetS components were included (n=6,699 participants). We used Poisson regression analysis to determine whether HsCRP was associated with incident MetS after adjusting for age, follow-up time, sex, Hispanic/Latino background, income, education, marital status, employment, health insurance status, nativity, alcohol use, smoking, anxiety, CESD-10, physical activity, and diet. All analyses included sample weights and accounted for the complex survey design of the study. Results: Mean age was 38.2 years, 29.0% had less than a high school education, 59.7% had an income less than $30,000, and 48.4% were female. Average follow-up time was 6.1 years. In fully adjusted models, moderate vs. low HsCRP was associated with a 39% increased risk of MetS (IDR: 1.39, 95% CI: 1.13, 1.71), while high vs. low HsCRP was associated with a 109% increased risk of MetS (IDR: 2.09, 95% CI: 1.70, 2.57). Conclusions: Greater levels of HsCRP were associated with new onset of MetS in a diverse sample of U.S. Hispanics/Latinos. Results suggest that HsCRP may be an independent risk factor for, rather than a marker of MetS.
Abstract 11311: Geographic Variation and Temporal Trends in Management and Outcomes of Cardiac Arrest Complicating Acute Myocardial Infarction in the United States
Authors: Sri Patlolla, Auras R Atreya, Saraschandra Vallabhajosyula
Journal: Circulation (2021)

Introduction: Regional variation in the uptake of newer techniques, procedures, and management strategies have been previously reported with acute cardiac care. Limited contemporary information exists on regional differences in the care of acute myocardial infarction (AMI) patients with cardiac arrest (CA). Methods: Using the National Inpatient Sample (2000-2017), we identified adults with AMI and concomitant CA admitted to the United States census regions of Northeast, Midwest, South, and West. Clinical outcomes of interest including in-hospital mortality, use of coronary angiography, percutaneous coronary intervention (PCI), mechanical circulatory support (MCS), hospitalization costs, and length of stay were compared across these four regions. Results: Of 9,680,257 admissions for AMI, 494,083 (5.1%) had concomitant CA. The prevalence of CA in AMI was highest in the West (6.0%) compared to the Northeast (4.4%), Midwest (5.0%), and South (5.1%), p&lt;0.001. Admissions in the West had higher rates of STEMI presentation, cardiogenic shock, multiorgan failure, mechanical ventilation, and hemodialysis. Northeast AMI-CA admissions had lower use of coronary angiography (52.0% vs. 67.9% vs. 60.9% vs. 61.5%), PCI (38.7% vs. 51.9% vs. 44.8% vs. 46.7%), and MCS (18.4% vs. 21.8% vs. 18.1%, vs. 20.0%) compared to the Midwest, West and South (all p&lt;0.001). Compared with the Northeast, adjusted in-hospital mortality for AMI-CA was higher in the Midwest (odds ratio [OR] 1.06 [95% confidence interval {CI} 1.03-1.08]; p&lt;0.001), South (OR 1.11 [95% CI 1.09-1.13]; p&lt;0.001), and highest in the West (OR 1.16 [95% CI 1.13-1.18]; p&lt;0.001). Temporal trends showed a decline in in-hospital mortality except in the West, which showed a slight increase. Compared to other regions, AMI-CA admissions from the Northeast had longer in-hospital stays and less frequent palliative care consultations (all p&lt;0.001). Admissions in the West had higher rates of palliative care consultations, DNR status, and highest hospitalization costs. Conclusions: We identified significant regional disparities in the management and outcomes of AMI-CA. Efforts to improve and provide uniform care for AMI-CA across regions may be essential.
26P Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung Cancer (aNSCLC): Updated results from GEOMETRY mono-1
Authors: J. Wolf, E.B. Garon, H.J.M. Groen, D.S.W. Tan, A. Robeva, S. Le Mouhaer, M. Carbini, A. Yovine, R. Heist
Journal: Annals of Oncology (2022)
Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality
Authors: Tomoko Nakanishi, Sara Pigazzini, Frauke Degenhardt, Mattia Cordioli, Guillaume Butler-Laporte, Douglas Maya-Miles, Luis Bujanda, Youssef Bouysran, Mari E.K. Niemi, Adriana Palom, David Ellinghaus, Atlas Khan, Manuel Martínez-Bueno, Selina Rolker, Sara Amitrano, Luisa Roade Tato, Francesca Fava, Christoph D. Spinner, Daniele Prati, David Bernardo, Federico Garcia, Gilles Darcis, Israel Fernández-Cadenas, Jan Cato Holter, Jesus M. Banales, Robert Frithiof, Krzysztof Kiryluk, Stefano Duga, Rosanna Asselta, Alexandre C. Pereira, Manuel Romero-Gómez, Beatriz Nafría-Jiménez, Johannes R. Hov, Isabelle Migeotte, Alessandra Renieri, Anna M. Planas, Kerstin U. Ludwig, Maria Buti, Souad Rahmouni, Marta E. Alarcón-Riquelme, Eva C. Schulte, Andre Franke, Tom H. Karlsen, Luca Valenti, Hugo Zeberg, J. Brent Richards, Andrea Ganna
Journal: Journal of Clinical Investigation (2021)

Background. There is considerable variability in COVID-19 outcomes among younger adults, and some of this variation may be due to genetic predisposition.
Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage
Authors: James Isaacs, Aaron C. Tan, Brent A. Hanks, Xiaofei Wang, Kouros Owzar, James E. Herndon, Scott J. Antonia, Steven Piantadosi, Mustafa Khasraw
Journal: Clinical Cancer Research (2021)

Clinical trials that have a pharmacokinetic or a pharmacodynamic immunologic mechanism of action–based primary outcome could substantially improve the validity and efficiency of early development of immuno-oncology agents. Here, we outline different trial design options in this area, review examples from the literature and their unique immunologic aspects, and highlight how these trials have been underutilized. We illustrate how new technologies and translationally focused approaches can be successfully used to develop different classes of immunotherapeutic agents.
Carditis After COVID-19 Vaccination With a Messenger RNA Vaccine and an Inactivated Virus Vaccine
Authors: Francisco Tsz Tsun Lai, Xue Li, Kuan Peng, Lei Huang, Patrick Ip, Xinning Tong, Celine Sze Ling Chui, Eric Yuk Fai Wan, Carlos King Ho Wong, Esther Wai Yin Chan, David Chung Wah Siu, Ian Chi Kei Wong
Journal: Annals of Internal Medicine (2022)

Background: Case reports of carditis after BNT162b2 vaccination are accruing worldwide. Objective: To examine the association of BNT162b2 and CoronaVac (Sinovac) vaccination with carditis. Design: Case–control study with hospital control participants. Setting: Territory-wide, public health care database with linkage to population-based vaccination records in Hong Kong. Patients: Inpatients aged 12 years or older first diagnosed with carditis were selected as case patients. All other hospitalized patients without carditis were treated as control participants. Ten control participants were randomly matched with each case patient by age, sex, and admission date. Intervention: Vaccination with BNT162b2 or CoronaVac. Measurements: Incident diagnosis of carditis based on the International Classification of Diseases, Ninth Revision, and elevated troponin levels. Results: A total of 160 case patients and 1533 control participants were included. Incidence of carditis per 100 000 doses of CoronaVac and BNT162b2 administered was estimated to be 0.31 (95% CI, 0.13 to 0.66) and 0.57 (CI, 0.36 to 0.90), respectively. Multivariable analyses showed that recipients of the BNT162b2 vaccine had higher odds of carditis (adjusted odds ratio [OR], 3.57 [CI, 1.93 to 6.60]) than unvaccinated persons. Stratified by sex, the OR was 4.68 (CI, 2.25 to 9.71) for males and 2.22 (CI, 0.57 to 8.69) for females receiving the BNT162b2 vaccine. The ORs for adults and adolescents receiving the BNT162b2 vaccine were 2.41 (CI, 1.18 to 4.90) and 13.79 (CI, 2.86 to 110.38), respectively. Subanalysis showed an OR of 9.29 (CI, 3.94 to 21.91) for myocarditis and 1.06 (CI, 0.35 to 3.22) for pericarditis associated with BNT162b2. The risk was mainly seen after the second dose of BNT162b2 rather than the first. No association between CoronaVac and carditis with a magnitude similar to that for BNT162b2 was seen. Limitation: Limited sample size, absence of electrocardiography and other clinical investigative data, and unrecorded overseas vaccination exposure. Conclusion: Despite a low absolute risk, there is an increased risk for carditis associated with BNT162b2 vaccination. This elevated risk should be weighed against the benefits of vaccination. Primary Funding Source: Health and Medical Research Fund.
Abstract EP14: Traditional And Non-traditional Cardiometabolic Risk Factors For Type 2 Myocardial Infarction Compared To Type 1 Myocardial Infarction In Young Women (18-44 Years): A National Inpatient Analysis
Authors: Akhil Jain, Preeti Agarwala, Ozo Akah, Shristee Ghimire, Samir Ghimire, Jilmil Raina, Vikram Itare, Sohiel Deshpande, Thomas Alukal, Melissa Alvarez, Rupak Desai
Journal: Circulation (2022)

Background: There has been growing interest in studying demand ischemia as a cause of type 2 myocardial infarction (T2MI) in younger patients. Conventional cardiovascular risk factors and their association (and degree) are vaguely defined as predictors of T2MI. Women may be noted to have different predictors given their underrepresentation in clinical trials. Methods: We analyzed young female (18-44 years) hospitalizations from the National Inpatient Sample 2018 for multivariate-adjusted predictors (aOR, 95% confidence interval) of T2MI, STEMI and NSTEMI admissions, and divided the significance level into p&lt;0.01, p&lt;0.05 &amp; p&lt;0.1. Results: Young females (n=6,152,028) had 0.05% STEMI, 0.16% NSTEMI and 0.08% T2MI admissions. Predictors (Table 1) with the highest significance level of association for T2MI (p&lt;0.01), compared to ST/NSTEMI (either 0.01&lt;p&lt;0.05 or not significant), were black race (aOR 1.49) and CHF (aOR 1.97), pulmonary circulation disorder (aOR 1.83) and OSA (aOR 1.62). Valvular heart disease, paralysis, COPD, deficiency anemia predicted a higher risk of T2MI admissions in young women (p&lt;0.05) but not STEMI/NSTEMI admissions. Hypertension, prior MI, dyslipidemia, family history of coronary artery disease, peripheral vascular disease, coagulopathy and fluid-electrolyte disorder predicted a higher risk of T2MI or STEMI/NSTEMI. Collagen vascular disorders and obesity had a higher risk of T2MI/NSTEMI (p&lt;0.01) but not of STEMI (p=0.07). DM, and cocaine abuse predicted higher odds of STEMI/NSTEMI but not of T2MI. Hypothyroid, liver disease, metastatic cancer, AIDS, depression, alcohol abuse and cannabis abuse did not predict a higher risk of T2MI or STEMI/NSTEMI. Hypothyroid, liver disease, metastatic cancer, AIDS, depression, alcohol and cannabis abuse did not predict higher odds of T2MI or STEMI/NSTEMI in young women. Conclusion: Predictors associated with T2MI in young females with a higher order of significance than ST/NSTEMI can be utilized to build a risk score for T2MI in young females.
18F-FDG PET/CT in Primary Intraosseous Squamous Cell Carcinoma
Authors: Shuai Lin, Na Fang, Jing Zhang, Yan-Li Wang
Journal: Clinical Nuclear Medicine (2022)

Abstract Primary intraosseous squamous cell carcinoma is a highly malignant but rare tumor within jaws. We reported the 18 F-FDG PET/CT findings of primary intraosseous squamous cell carcinoma of the mandible in a 42-year-old man. 18 F-FDG PET/CT identified a cystic lesion in the mandible with irregular annular uptake of 18 F-FDG, which has been confirmed as primary intraosseous squamous cell carcinoma pathologically.